<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982939</url>
  </required_header>
  <id_info>
    <org_study_id>PERSIST</org_study_id>
    <nct_id>NCT04982939</nct_id>
  </id_info>
  <brief_title>Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer</brief_title>
  <official_title>Efficacy and Safety of Peri-operative Sintilimab in Combination With SOX in Resectable Locally Advanced Gastric Cancer: a Multiple-center Open-label Randomized Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in&#xD;
      resectable locally advanced gastric or gastroesophageal junction adenocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">June 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR) rate</measure>
    <time_frame>up to 8 weeks after surgery</time_frame>
    <description>Pathological complete response (pCR) rate is defined as the proportion of participants whose tumor in the stomach and lymph node completely disappeared, as determined by a pathologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor down-staging rate</measure>
    <time_frame>up to 8 weeks after surgery</time_frame>
    <description>Tumor down-staging is defined as any stage reduction between clinical and pathologic stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathological response (MPR) rate</measure>
    <time_frame>up to 8 weeks after surgery</time_frame>
    <description>Major pathological response (MPR) rate is defined as the proportion of participants whose percentage of residual tumor in the stomach and lymph node decreased to &lt; 10%, as determined by a pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 years disease-free survival (DFS) rate</measure>
    <time_frame>up to 4 years</time_frame>
    <description>3 years disease-free survival (DFS) rate is defined as proportion of participants who have no recurrence or metastasis after 3 years of radical treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 years overall survival (OS) rate</measure>
    <time_frame>up to 6 years</time_frame>
    <description>5 years overall survival (OS) rate is defined as proportion of participants who survived 5 years after radical treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>up to 30 days after last treatment administration</time_frame>
    <description>All grades of adverse events, all grades of treatment related adverse events, serious of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate ( ORR)</measure>
    <time_frame>up to 30 days after last preoperative treatment administration</time_frame>
    <description>Overall response rate ( ORR) is defined as proportion of participants who have a best response of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 30 days after last preoperative treatment administration</time_frame>
    <description>Disease Control Rate (DCR) is defined as proportion of participants who have a best response of CR、PR or SD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Perioperative</condition>
  <condition>Sintilimab</condition>
  <arm_group>
    <arm_group_label>Experimental Group-Sintilimab in combination with SOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative treatment: three cycles of sintilimab in combination with SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX, Sintilimab up to one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator-SOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative treatment: three cycles of SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab, 200mg IV d1 Q3W</description>
    <arm_group_label>Experimental Group-Sintilimab in combination with SOX</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1, 40-60mg BID d1-14 Q3W</description>
    <arm_group_label>Active Comparator-SOX</arm_group_label>
    <arm_group_label>Experimental Group-Sintilimab in combination with SOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin，130mg/m2 d1 Q3W</description>
    <arm_group_label>Active Comparator-SOX</arm_group_label>
    <arm_group_label>Experimental Group-Sintilimab in combination with SOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 18 years old ≤ age ≤ 75 years old&#xD;
&#xD;
          -  ECOG PS score 0-1&#xD;
&#xD;
          -  Treatment naive patients diagnosed as gastric adenocarcinoma or gastroesophageal&#xD;
             junction adenocarcinoma by histopathology&#xD;
&#xD;
          -  No known HER2-positive status;&#xD;
&#xD;
          -  Clinical stage Ⅱ, Ⅲ (T1-4a N+ M0, T3-4a N0 M0, AJCC 8th)&#xD;
&#xD;
          -  The research center and the surgeon can complete D2 radical gastrectomy&#xD;
&#xD;
          -  Physical condition and organ function allow for larger abdominal surgery&#xD;
&#xD;
          -  Sufficient organ and bone marrow function, which is defined as follows:&#xD;
&#xD;
               1. Blood routine: absolute neutrophil count (ANC)≥1.5×109/L; platelet count&#xD;
                  (PLT)≥100×109/L; hemoglobin content (HGB)≥9.0 g/dL.&#xD;
&#xD;
               2. Liver function: Patients without liver metastasis require serum total bilirubin&#xD;
                  (TBIL) ≤1.5×upper limit of normal (ULN); alanine aminotransferase (ALT) and&#xD;
                  aspartate aminotransferase (AST) ≤2.5 ×ULN;&#xD;
&#xD;
               3. Renal function: Creatinine clearance rate (Ccr) ≥50 mL/min (calculated by&#xD;
                  Cockcroft/Gault formula):&#xD;
&#xD;
                    1. Female: Ccr= (140-years old) x weight (kg) x 0.85/(72 x serum creatinine&#xD;
                       (mg/dL))&#xD;
&#xD;
                    2. Male: Ccr= (140-years old) x weight (kg) x 1.00/(72 x serum creatinine&#xD;
                       (mg/dL))&#xD;
&#xD;
               4. The coagulation function is adequate, defined as the international normalized&#xD;
                  ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; if the subject is receiving&#xD;
                  anticoagulation therapy, as long as the PT is within the proposed range of&#xD;
                  anticoagulation drugs&#xD;
&#xD;
          -  LVEF≥50%;&#xD;
&#xD;
          -  Agree and be able to comply with the plan during the research period;&#xD;
&#xD;
          -  Provide written informed consent before entering the study screening, and the patient&#xD;
             has understood that participants can withdraw from the study at any time during the&#xD;
             study without any loss;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complicated with upper gastrointestinal obstruction/bleeding or abnormal digestive&#xD;
             function or malabsorption syndrome;&#xD;
&#xD;
          -  Complicated with severe uncontrolled concurrent infection or other severe uncontrolled&#xD;
             concomitant disease, moderate or severe renal injury;&#xD;
&#xD;
          -  Received previous anti-tumor therapy, including chemotherapy, radiotherapy, targeted&#xD;
             therapy or immunotherapy, etc.;&#xD;
&#xD;
          -  Suffered from other malignant tumors in the past 5 years (except basal cell or&#xD;
             squamous cell carcinoma, superficial bladder cancer, cervical cancer in situ or breast&#xD;
             cancer);&#xD;
&#xD;
          -  Uncontrollable pleural effusion, pericardial effusion or ascites;&#xD;
&#xD;
          -  Suffered from severe cardiovascular disease within 12 months before enrollment, such&#xD;
             as symptomatic coronary heart disease, congestive heart failure ≥ Grade II,&#xD;
             uncontrolled arrhythmia, and myocardial infarction;&#xD;
&#xD;
          -  Allergic reactions to the drugs used in this study;&#xD;
&#xD;
          -  Use steroids or other systemic immunosuppressive therapies 14 days before enrollment;&#xD;
&#xD;
          -  Patients who received study drug treatment within 4 weeks before enrollment&#xD;
             (participate in other clinical trials);&#xD;
&#xD;
          -  Active autoimmune diseases;&#xD;
&#xD;
          -  History of primary immunodeficiency;&#xD;
&#xD;
          -  Have used immunosuppressive drugs within 4 weeks before the first dose of study&#xD;
             treatment, excluding nasal spray, inhaled or other local glucocorticoids or&#xD;
             physiological doses of systemic glucocorticoids (that is, no more than 10 mg/day Pred&#xD;
             nisone or other glucocorticoids in equivalent doses), or use hormones to prevent&#xD;
             allergy to contrast agents;&#xD;
&#xD;
          -  Within 4 weeks before the first dose of study treatment or plan to receive live&#xD;
             attenuated vaccine during the study period;&#xD;
&#xD;
          -  Known to have active tuberculosis;&#xD;
&#xD;
          -  Known history of allogeneic organ transplantation and allogeneic hematopoietic stem&#xD;
             cell transplantation;&#xD;
&#xD;
          -  HIV antibody positive, active hepatitis B or C (HBV, HCV);&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Liang, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute &amp; Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xuewei Ding, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute &amp; Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuewei ding, PhD.</last_name>
    <phone>18622220158</phone>
    <email>xding@tmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuewei Ding, PhD.</last_name>
      <phone>18622220158</phone>
      <email>xding@tmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

